



EXPANDED ACCESS POLICY

CalciMedica is developing medicines for the treatment of inflammatory diseases. As we advance our pipeline, patients, caregivers, and healthcare providers may seek access to our investigational medicines outside of clinical trials and prior to regulatory approval. We understand the need for new therapies and the urgency behind requests for pre-approval access*.

While we continue evaluating the safety and effectiveness of our product candidates in clinical trials, we are not providing access to our investigational medicines outside of these trials. We believe that participation in a clinical trial is the most appropriate way for patients to access our investigational therapies. Should our policy change over time, we will post updates on this site.

You can find links to information about our ongoing clinical trials on our website or go directly to www.clinicaltrials.gov and enter “CalciMedica” into the “other terms” search box.

If you have any questions, please reach out to us at info@calcimedica.com. You can find further contact details on the Contact Us page of our website.

**Includes requests for access under section 561(b) of the Federal Food, Drug, and Cosmetic Act, as well as ‘Right to Try’ legislation (Public law no. 115-176).*